Brief: Sanofi's Dupixent Approved In The EU As First Targeted Medicine For Young Children With CSU
13/04/2026 06:54
April 13 (Reuters) - Sanofi SA SASY.PA: EU APPROVES DUPIXENT AS FIRST TARGETED MEDICINE FOR YOUNG CHILDREN WITH CSU DUPIXENT IS NOW APPROVED FOR CHILDREN AGED TWO TO 11 YEARS IN EU ACROSS FOUR CHRONIC DISEASES DRIVEN IN PART BY TYPE 2 INFLAMMATION Source text: ID: nGNE77wXZh Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes